SCHEMBL4554142

SCHEMBL4554142

O=C1Cc2ccc3c(c2N1)C(=O)CCC3

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHR P35869 5/20 0.43
PARP1 P09874 1/20 0.38
MAPT P10636 1/20 0.37
MAOA P21397 2/20 0.36
MAOB P27338 2/20 0.36
PDK2 Q15119 1/20 0.36
CYP2A6 P11509 1/20 0.36
CMA1 P23946 2/20 0.36
EIF2AK2 P19525 1/20 0.35
TDP2 O95551 7/20 0.34
CASP3 P42574 1/20 0.34
CASP7 P55210 1/20 0.34
CASP9 P55211 1/20 0.34
CASP6 P55212 1/20 0.34
CASP8 Q14790 1/20 0.34
MAP3K14 Q99558 1/20 0.34
HSD17B1 P14061 1/20 0.33
PRKCI P41743 1/20 0.33
MEN1 O00255 1/20 0.33
MAPK1 P28482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18289475 0.76 AHR (0.59) AHRPDK2CMA1EIF2AK2TDP2
SCHEMBL17744153 0.67 PARP1 (0.44) AHRPARP1MAPTPDK2CMA1
SCHEMBL4690922 0.65 NR3C2 (0.41) PARP1MAPTKMT2ANPSR1
SCHEMBL16320760 0.64 AHR (0.61) AHRPDK2CMA1EIF2AK2TDP2
SCHEMBL18289462 0.64 AHR (0.52) AHRPDK2CMA1EIF2AK2TDP2
SCHEMBL22778223 0.64 MAOA (0.39) PARP1MAPTMAOAMAOBCYP2A6
SCHEMBL14555362 0.64 AHR (0.47) AHRMAPTPDK2CMA1EIF2AK2
SCHEMBL10805768 0.64 CYP1A2 (0.37) AHRPARP1MAPTMAOAMAOB
SCHEMBL31734656 0.63 AHR (0.42) AHRPARP1MAPTPDK2CMA1
SCHEMBL22349152 0.63 AHR (0.42) AHRMAPTPDK2CMA1EIF2AK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2134692-A2 QUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM FOR SELECTIN INHIBITION Wyeth a Corporation of the State of Delaware (US) 2009-12-23 EP disclosed
US-20080255192-A1 2-(1-(4-chlorophenyl)cyclopropyl)-3-hydroxy-8-(trifluoromethoxy)quinoline-4-carboxylic acid; antiinflammtory agents; antagonists of the mammalian adhesion proteins WYETH (US) 2008-10-16 US disclosed
WO-2008121817-A2 QUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM FOR SELECTIN INHIBITION WYETH (US) 2008-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255192-A1 2-(1-(4-chlorophenyl)cyclopropyl)-3-hydroxy-8-(trifluoromethoxy)quinoline-4-carboxylic acid; antiinflammtory agents; antagonists of the mammalian adhesion proteins VCAM1, ICAM1, SELE AHR 3473/4885PARP1 2723/4885MAPT 3723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.